“Getting Fast-Track designation is a critical milestone towards our goal of advancing PTX-100 into a
registration-enabling trial designed to support potential accelerated approval and, from there,
commercialisation. As we progress our Phase 2 trials, we will be engaging closely with the FDA to ensure
alignment on endpoints and study scope.”
This is going all the way to being commercialised, With a market cap of $34 million the upside here is enormous!
“Getting Fast-Track designation is a critical milestone towards...
Add to My Watchlist
What is My Watchlist?
